ATRST1
MCID: ATR087
MIFTS: 75

Atrial Standstill 1 (ATRST1)

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Atrial Standstill 1

MalaCards integrated aliases for Atrial Standstill 1:

Name: Atrial Standstill 1 56 12 73 29 6
Cardiomyopathy 62 39 17 32
Heart Block 43 62 71
Cardiomyopathy, Familial, with Conduction Disturbance 56 71
Atrial Cardiomyopathy with Heart Block 56 73
Cardiomyopathies 43 71
Atrst1 56 73
Familial Cardiomyopathy with Conduction Disturbance 73
Atrial Standstill, Digenic 56
Standstill, Atrial, Type 1 39

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
atrial standstill 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0080662
OMIM 56 108770
UMLS 71 C0018794 C0878544 C1838539

Summaries for Atrial Standstill 1

PubMed Health : 62 About cardiomyopathy: Cardiomyopathy (KAR-de-o-mi-OP-ah-thee) refers to diseases of the heart muscle. These diseases have many causes, signs and symptoms, and treatments. In cardiomyopathy, the heart muscle becomes enlarged, thick, or rigid. In rare cases, the muscle tissue in the heart is replaced with scar tissue. As cardiomyopathy worsens, the heart becomes weaker. It's less able to pump blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or irregular heartbeats called arrhythmias (ah-RITH-me-ahs). In turn, heart failure can cause fluid to build up in the lungs, ankles, feet, legs, or abdomen. The weakening of the heart also can cause other complications, such as heart valve problems.

MalaCards based summary : Atrial Standstill 1, also known as cardiomyopathy, is related to progressive familial heart block and cardiomyopathy, dilated, 1e, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Atrial Standstill 1 is GJA5 (Gap Junction Protein Alpha 5), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Verapamil and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and bone, and related phenotypes are first degree atrioventricular block and endocardial fibroelastosis

Disease Ontology : 12 A heart conduction disease that is characterized by a transient or permanent absence of electrical and mechanical atrial activity and that has material basis in coinheritance of a variant in the SCN5A gene in combination with a rare connexin-40 genotype.

OMIM : 56 Atrial standstill (AS) is a rare condition characterized by the absence of electrical and mechanical activity in the atria. On surface ECG, AS is distinguished by bradycardia, junctional (usually narrow complex) escape rhythm, and absence of the P wave. Nearly 50% of patients with AS experience syncope. AS can be persistent or transient, and diffuse or partial (summary by Fazelifar et al., 2005). (108770)

UniProtKB/Swiss-Prot : 73 Atrial standstill 1: A rare arrhythmia characterized by the absence of electrical and mechanical activity in the atria. Electrocardiographically, it is characterized by bradycardia, the absence of P waves, and a junctional narrow complex escape rhythm.

Related Diseases for Atrial Standstill 1

Diseases in the Atrial Standstill family:

Atrial Standstill 1 Atrial Standstill 2

Diseases related to Atrial Standstill 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2120)
# Related Disease Score Top Affiliating Genes
1 progressive familial heart block 35.4 TNNT2 GJA5 DSP
2 cardiomyopathy, dilated, 1e 35.1 TTN MYH7 LMNA DSP
3 cardiomyopathy, dilated, with woolly hair and keratoderma 34.9 RYR2 PKP2 DSP DSG2
4 cardiomyopathy, dilated, 1b 34.8 TTN MYH7 MYBPC3 LMNA
5 cardiomyopathy, familial hypertrophic, 4 34.7 TTN TNNT2 MYH7 MYBPC3 DMD
6 arrhythmogenic right ventricular cardiomyopathy 34.6 TTN RYR2 PRKAG2 PLN PKP2 MYL2
7 cardiomyopathy, dilated, 1dd 34.6 TTN RYR2
8 restrictive cardiomyopathy 34.6 TTR TTN TNNT2 TNNI3 MYL2 MYH7
9 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 34.4 RYR2 PKP2 MYH7 DSP
10 familial isolated restrictive cardiomyopathy 34.4 TNNT2 TNNI3 MYL2
11 naxos disease 34.2 RYR2 PKP2 DSP DSG2
12 extrinsic cardiomyopathy 34.2 TTN TNNT2 TNNI3
13 arrhythmogenic right ventricular dysplasia, familial, 11 34.2 RYR2 PKP2 DSG2
14 arrhythmogenic right ventricular dysplasia, familial, 13 34.1 RYR2 PKP2 DSP
15 familial isolated dilated cardiomyopathy 34.0 TTN TNNT2 TNNI3 TAZ PLN MYH7
16 emery-dreifuss muscular dystrophy 2, autosomal dominant 33.8 TTN LMNA DMD
17 arrhythmogenic right ventricular dysplasia, familial, 12 33.8 RYR2 PKP2 DSG2
18 arrhythmogenic right ventricular dysplasia, familial, 5 33.8 RYR2 PKP2 DSP DSG2
19 arrhythmogenic right ventricular dysplasia, familial, 10 33.8 RYR2 PKP2 DSP DSG2
20 arrhythmogenic right ventricular dysplasia, familial, 8 33.8 RYR2 PKP2 DSP DSG2
21 arrhythmogenic right ventricular dysplasia, familial, 1 33.7 TTN RYR2 PKP2 DSG2
22 intrinsic cardiomyopathy 33.7 TTN TNNT2 TNNI3 TAZ RYR2 PRKAG2
23 arrhythmogenic right ventricular dysplasia, familial, 9 33.7 RYR2 PLN PKP2 DSP DSG2
24 arrhythmogenic right ventricular dysplasia, familial, 2 33.7 RYR2 PKP2 DSP DSG2
25 arrhythmogenic right ventricular dysplasia, familial, 4 33.6 RYR2 PKP2 DSP DSG2
26 arrhythmogenic right ventricular dysplasia, familial, 3 33.6 RYR2 PKP2 DSP DSG2
27 arrhythmogenic right ventricular dysplasia, familial, 6 33.6 RYR2 PKP2 DSP DSG2
28 barth syndrome 33.6 TTR TAZ MYH7 MYBPC3
29 second-degree atrioventricular block 33.4 TNNI3 TAZ
30 atrioventricular block 33.2 TTN TNNI3 RYR2 MYH7 LMNA GJA5
31 right bundle branch block 33.1 TNNI3 PKP2 DSG2
32 myofibrillar myopathy 33.1 TTN MYH7 LMNA DMD
33 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 33.0 TTN RYR2 PKP2 LMNA DSP DSG2
34 glycogen storage disease ii 33.0 PRKAG2 LAMP2 DMD
35 familial woolly hair syndrome 33.0 RYR2 PKP2 DSP DSG2
36 noonan syndrome with multiple lentigines 33.0 TNNT2 TAZ RYR2 MYH7 MYBPC3
37 first-degree atrioventricular block 32.9 MYH7 LMNA
38 limb-girdle muscular dystrophy 32.9 TTN LMNA DMD
39 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 32.8 TTN RYR2 PKP2 LMNA DSP DSG2
40 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 32.8 TTN RYR2 PKP2 LMNA DSP DSG2
41 congenital fiber-type disproportion 32.6 TTN MYL2 MYH7 LMNA DMD ACTC1
42 holt-oram syndrome 32.5 MYH7 LMNA GJA5
43 muscular dystrophy, limb-girdle, autosomal recessive 6 32.5 TTN DMD
44 syncope 31.9 TTN TNNT2 RYR2
45 heart septal defect 31.8 TNNT2 GJA5 ACTC1
46 muscular dystrophy, duchenne type 31.8 TTN TNNT2 TNNI3 DMD
47 myocarditis 31.7 TNNI3 DSP DMD
48 left bundle branch hemiblock 31.5 TNNT2 TNNI3 RYR2 PKP2 LMNA DSP
49 ventricular fibrillation, paroxysmal familial, 1 31.5 TNNT2 RYR2 DSP
50 palmoplantar keratosis 31.3 PKP2 DSP DSG2

Comorbidity relations with Atrial Standstill 1 via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Atrial Standstill 1:



Diseases related to Atrial Standstill 1

Symptoms & Phenotypes for Atrial Standstill 1

Human phenotypes related to Atrial Standstill 1:

31
# Description HPO Frequency HPO Source Accession
1 first degree atrioventricular block 31 HP:0011705
2 endocardial fibroelastosis 31 HP:0001706
3 premature atrial contractions 31 HP:0006699
4 atrial standstill 31 HP:0025478
5 atrial cardiomyopathy 31 HP:0200127

Symptoms via clinical synopsis from OMIM:

56
Lab:
endocardial fibroelastosis

Cardiac:
atrial standstill
atrial cardiomyopathy
first-degree heart block
ectopic supraventricular rhythms
atrial inexcitability

Clinical features from OMIM:

108770

UMLS symptoms related to Atrial Standstill 1:


edema, chest pain, angina pectoris

GenomeRNAi Phenotypes related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.66 PRKAG2
2 Decreased viability GR00221-A-2 9.66 PRKAG2 TTN
3 Decreased viability GR00221-A-4 9.66 TTN
4 Decreased viability GR00240-S-1 9.66 LMNA
5 Decreased viability GR00249-S 9.66 GJA5 GLA LMNA RYR2 TNNT2 TTR
6 Decreased viability GR00342-S-1 9.66 TTN
7 Decreased viability GR00342-S-3 9.66 TTN
8 Decreased viability GR00381-A-1 9.66 GLA MYBPC3
9 Decreased viability GR00386-A-1 9.66 LMNA MYBPC3 TTR
10 Decreased viability GR00402-S-2 9.66 DMD DSP LAMP2 MYBPC3

MGI Mouse Phenotypes related to Atrial Standstill 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ACTC1 DMD DSG2 DSP GJA5 GLA
2 homeostasis/metabolism MP:0005376 10.13 ACTC1 DMD GJA5 GLA LAMP2 LMNA
3 cellular MP:0005384 10.06 ACTC1 DMD DSG2 DSP GLA LAMP2
4 mortality/aging MP:0010768 10.03 ACTC1 DMD DSG2 DSP GJA5 GLA
5 muscle MP:0005369 9.89 ACTC1 DMD DSG2 DSP GJA5 GLA
6 normal MP:0002873 9.28 ACTC1 DMD GJA5 LMNA MYH7 MYL2

Drugs & Therapeutics for Atrial Standstill 1

PubMed Health treatment related to Atrial Standstill 1: 62

People who have cardiomyopathy but no signs or symptoms may not need treatment . Sometimes, dilated cardiomyopathy that comes on suddenly may even go away on its own. For other people who have cardiomyopathy , treatment is needed. Treatment depends on the type of cardiomyopathy you have, the severity of your symptoms and complications, and your age and overall health. The main goals of treating cardiomyopathy include: Managing any conditions that cause or contribute to the disease Controlling signs and symptoms so that you can live as normally as possible Stopping the disease from getting worse Reducing complications and the risk of sudden cardiac arrest (SCA) Treatments may include lifestyle changes, medicines, surgery , implanted devices to correct arrhythmias (irregular heartbeats ), and/or a nonsurgical procedure.

Drugs for Atrial Standstill 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 479)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verapamil Approved Phase 4 52-53-9 2520
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
4
Empagliflozin Approved Phase 4 864070-44-0
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Chlorthalidone Approved Phase 4 77-36-1 2732
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
9
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
13
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
14
Doxazosin Approved Phase 4 74191-85-8 3157
15
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
16
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
17
Deferiprone Approved Phase 4 30652-11-0 2972
18
Ramipril Approved Phase 4 87333-19-5 5362129
19
Hydralazine Approved Phase 4 86-54-4 3637
20
Glucagon Approved Phase 4 16941-32-5
21
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
22
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
23
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
24
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
25
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
26
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
27
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
28
Meperidine Approved Phase 4 57-42-1 4058
29
Testosterone enanthate Approved Phase 4 315-37-7 9416
30
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
31
Methyltestosterone Approved Phase 4 58-18-4 6010
32
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
33
Ezetimibe Approved Phase 4 163222-33-1 150311
34
Phenoxybenzamine Approved Phase 4 59-96-1 4768
35
leucovorin Approved Phase 4 58-05-9 6006 143
36
Propafenone Approved Phase 4 54063-53-5 4932
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
40
tannic acid Approved Phase 4 1401-55-4
41
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
42
Adalimumab Approved Phase 4 331731-18-1 16219006
43
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
44
Tofacitinib Approved, Investigational Phase 4 477600-75-2
45
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
46
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
47
Selenious acid Approved, Investigational Phase 4 7783-00-8
48
Probenecid Approved, Investigational Phase 4 57-66-9 4911
49
Ethanol Approved Phase 4 64-17-5 702
50
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925

Interventional clinical trials:

(show top 50) (show all 1490)
# Name Status NCT ID Phase Drugs
1 Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness. Unknown status NCT01904396 Phase 4 Carnitine
2 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Unknown status NCT00879060 Phase 4 spironolactone
3 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
4 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
5 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
6 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
7 A Randomised, Double-Blinded, Placebo-Controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone Unknown status NCT00401856 Phase 4 Eplerenone;Placebo
8 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
9 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Unknown status NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
10 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
11 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Unknown status NCT02592889 Phase 4
12 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
13 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
14 Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
15 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
16 Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study. Unknown status NCT00819845 Phase 4 carvedilol;ramipril
17 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
18 A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
19 The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients Unknown status NCT03271879 Phase 4 Empagliflozin at a dose of 10 mg/day
20 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
21 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
22 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
23 A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
24 Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation Completed NCT01721967 Phase 4 Ranolazine
25 Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study Completed NCT01345188 Phase 4 Ranexa;Placebo
26 Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
27 Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
28 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Completed NCT03249272 Phase 4 Regadenoson;Adenosine
29 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
30 Effect of Aldosterone on Energy Starvation in Heart Failure Completed NCT00574119 Phase 4 spironolactone
31 ACC - Atrial Contribution to CRT Completed NCT00180323 Phase 4
32 A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy Completed NCT01293903 Phase 4 Qiliqiangxin capsule;Placebo
33 Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Completed NCT01181414 Phase 4 Beta blocker/digoxine/amiodarone
34 Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
35 Pilot Study to Assess the Effect of Low Dose Epoetin Beta Administered for Six Month in Patients With Ischemic Heart Failure Subjected to Percutaneous Coronary Intervention (PCI) Completed NCT00568542 Phase 4 erythropoetin beta;placebo
36 Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study Completed NCT01534026 Phase 4 Aspirin
37 Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy Completed NCT02053974 Phase 4 Spironolactone
38 Clinical Evaluation on Advanced Resynchronization Completed NCT00658203 Phase 4
39 Statin Induced Augmentation of Circulating Endothelial Progenitor Cells and Myocardial Viability in Patients With Ischemic and Nonischemic Cardiomyopathy Completed NCT00701220 Phase 4 Atorvastatin Calcium
40 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
41 Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment Completed NCT00559338 Phase 4 recombinant B-type, natriuretic peptide;placebo
42 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS) Completed NCT00621621 Phase 4
43 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
44 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
45 Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter Completed NCT00180557 Phase 4
46 123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging Completed NCT01868841 Phase 4 AdreView
47 Pacing for Cardiomyopathies, a European Study- A Therapy Acceptance Study Completed NCT00180596 Phase 4
48 Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients Completed NCT00477789 Phase 4 allopurinol
49 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
50 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment

Search NIH Clinical Center for Atrial Standstill 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dopamine
Dopamine Hydrochloride
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
Isoproterenol
Isoproterenol Hydrochloride
Isoproterenol Sulfate
Racepinephrine Hydrochloride

Cochrane evidence based reviews: heart block

Genetic Tests for Atrial Standstill 1

Genetic tests related to Atrial Standstill 1:

# Genetic test Affiliating Genes
1 Atrial Standstill 1 29 GJA5

Anatomical Context for Atrial Standstill 1

MalaCards organs/tissues related to Atrial Standstill 1:

40
Heart, Testes, Bone, Liver, Endothelial, Brain, Bone Marrow

Publications for Atrial Standstill 1

Articles related to Atrial Standstill 1:

(show top 50) (show all 30370)
# Title Authors PMID Year
1
Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. 6 61
20152563 2010
2
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6 61
20031617 2009
3
Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. 6 61
16774985 2006
4
Familial atrial standstill in association with dilated cardiomyopathy. 61 56
16176547 2005
5
Familial atrial cardiomyopathy with heart block. 56 61
4636548 1972
6
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 6
21810866 2011
7
A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. 6
20840742 2010
8
Congenital atrial standstill associated with coinheritance of a novel SCN5A mutation and connexin 40 polymorphisms. 56
16188595 2005
9
A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. 56
12522116 2003
10
Familial total atrial standstill. 56
1575158 1992
11
Familial atrial dysrhythmia with A-V block. Intracellular microelectrode, clinical electrophysiologic, and morphologic observations. 56
4430108 1974
12
Atrial standstill: a review, and presentation of two new cases of familial and unususal nature with reference to epicardial pacing in one. 56
5347950 1969
13
Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. 61 54
20439823 2010
14
Cardiomyocyte-targeted overexpression of the coxsackie-adenovirus receptor causes a cardiomyopathy in association with beta-catenin signaling. 61 54
20144615 2010
15
Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation. 54 61
20083571 2010
16
Nesprin-1 mutations in human and murine cardiomyopathy. 61 54
19944109 2010
17
Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. 54 61
19026577 2010
18
Familial dilated cardiomyopathy secondary to dystrophin splice site mutation. 61 54
20206892 2010
19
A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. 61 54
20044516 2010
20
Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. 61 54
20101000 2010
21
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. 61 54
19815563 2010
22
Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. 61 54
19864899 2010
23
Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. 54 61
20031633 2009
24
Rippling muscle disease and cardiomyopathy associated with a mutation in the CAV3 gene. 61 54
19773168 2009
25
Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. 61 54
20031619 2009
26
Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. 46
19641226 2009
27
Lamin A/C gene mutations in familial cardiomyopathy with advanced atrioventricular block and arrhythmia. 61 54
19638735 2009
28
Association of angiotensin-converting enzyme activity and polymorphism with echocardiographic measures in familial and nonfamilial hypertrophic cardiomyopathy. 61 54
19390744 2009
29
Severe infantile-onset cardiomyopathy associated with a homozygous deletion in desmin. 54 61
19433360 2009
30
Familial amyloid cardiomyopathy due to TTR mutations: an underdiagnosed cause of restrictive cardiomyopathy [corrected]. 61 54
19477408 2009
31
[Anthracycline-induced cardiomyopathy]. 61 54
19423276 2009
32
Unique epidermolytic bullous dermatosis with associated lethal cardiomyopathy related to novel desmoplakin mutations. 54 61
19178614 2009
33
Mutations of plakophilin-2 in Chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 61 54
19427443 2009
34
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. 61 54
19233868 2009
35
Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with Chagasic cardiomyopathy. 61 54
19452608 2009
36
MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. 46
19380620 2009
37
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. 61 54
19279339 2009
38
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. 54 61
19318653 2009
39
Stress-induced (Takotsubo) cardiomyopathy: a transient disorder. 54 61
17651835 2009
40
Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. 61 54
19399179 2009
41
Catecholamine-induced cardiomyopathy. 54 61
19158054 2008
42
Anthracycline-induced cardiomyopathy. 61 54
19020367 2008
43
Dystrophin: from non-ischemic cardiomyopathy to ischemic cardiomyopathy. 54 61
18562127 2008
44
Role of coxsackievirus and adenovirus receptor in the pathogenesis of dilated cardiomyopathy and its influencing factor. 61 54
18959124 2008
45
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. 61 54
18445662 2008
46
Claudin-5 levels are reduced in human end-stage cardiomyopathy. 54 61
18513742 2008
47
A novel G3337A mitochondrial ND1 mutation related to cardiomyopathy co-segregates with tRNALeu(CUN) A12308G and tRNAThr C15946T mutations. 54 61
18502698 2008
48
Cardiomyopathy and carnitine deficiency. 54 61
18337137 2008
49
Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. 54 61
18282207 2008
50
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? 61 54
18069997 2008

Variations for Atrial Standstill 1

ClinVar genetic disease variations for Atrial Standstill 1:

6 (show top 50) (show all 4152) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KCNE1 NM_000219.6(KCNE1):c.253G>A (p.Asp85Asn)SNV Conflicting interpretations of pathogenicity, other, risk factor 13479 rs1805128 21:35821680-35821680 21:34449382-34449382
2 SCN1B NM_001037.5(SCN1B):c.308A>T (p.Asp103Val)SNV Pathogenic 375404 rs1057519457 19:35524503-35524503 19:35033599-35033599
3 MYBPC3 NM_000256.3(MYBPC3):c.2311dup (p.Val771fs)duplication Pathogenic 42615 rs397515960 11:47359342-47359343 11:47337791-47337792
4 MYBPC3 NM_000256.3(MYBPC3):c.2373dup (p.Trp792fs)duplication Pathogenic 42619 rs397515963 11:47359281-47359281 11:47337729-47337730
5 MYBPC3 NM_000256.3(MYBPC3):c.2534_2538del (p.Arg845fs)deletion Pathogenic 42635 rs397515973 11:47359006-47359010 11:47337455-47337459
6 MYBPC3 NM_000256.3(MYBPC3):c.2905C>T (p.Gln969Ter)SNV Pathogenic 42669 rs397515992 11:47356593-47356593 11:47335042-47335042
7 MYBPC3 NM_000256.3(MYBPC3):c.3181C>T (p.Gln1061Ter)SNV Pathogenic 42690 rs397516005 11:47355117-47355117 11:47333566-47333566
8 MYBPC3 NM_000256.3(MYBPC3):c.3624del (p.Lys1209fs)deletion Pathogenic 42727 rs397516029 11:47354120-47354120 11:47332569-47332569
9 MYBPC3 NM_000256.3(MYBPC3):c.436dup (p.Thr146fs)duplication Pathogenic 42751 rs397516049 11:47371633-47371634 11:47350082-47350083
10 MYBPC3 NM_000256.3(MYBPC3):c.551dup (p.Lys185fs)duplication Pathogenic 42771 rs397516059 11:47371427-47371428 11:47349876-47349877
11 MYBPC3 NM_000256.3(MYBPC3):c.927-9G>ASNV Pathogenic 42807 rs397516083 11:47367930-47367930 11:47346379-47346379
12 MYH7 NM_000257.4(MYH7):c.1988G>A (p.Arg663His)SNV Pathogenic 42875 rs371898076 14:23896042-23896042 14:23426833-23426833
13 MYH7 NM_000257.4(MYH7):c.2681A>G (p.Glu894Gly)SNV Pathogenic 42922 rs397516161 14:23893357-23893357 14:23424148-23424148
14 MYH7 NM_000257.4(MYH7):c.788T>C (p.Ile263Thr)SNV Pathogenic 43106 rs397516269 14:23900635-23900635 14:23431426-23431426
15 TNNI3 NM_000363.5(TNNI3):c.470C>T (p.Ala157Val)SNV Pathogenic 43388 rs397516353 19:55665477-55665477 19:55154109-55154109
16 PLN NM_002667.5(PLN):c.37_39AGA[1] (p.Arg14del)short repeat Pathogenic 44580 rs397516784 6:118880120-118880122 6:118558957-118558959
17 PKP2 NM_001005242.3(PKP2):c.1237C>T (p.Arg413Ter)SNV Pathogenic 45016 rs372827156 12:33003841-33003841 12:32850907-32850907
18 PKP2 NM_001005242.2(PKP2):c.148_151del (p.Thr50fs)deletion Pathogenic 45028 rs397516997 12:33049515-33049518 12:32896581-32896584
19 PKP2 NM_001005242.3(PKP2):c.2065_2070delinsG (p.His689fs)indel Pathogenic 45063 rs397517021 12:32955434-32955439 12:32802500-32802505
20 PLN NM_002667.5(PLN):c.25C>T (p.Arg9Cys)SNV Pathogenic 13636 rs111033559 6:118880109-118880109 6:118558946-118558946
21 MYH7 NM_000257.4(MYH7):c.1357C>T (p.Arg453Cys)SNV Pathogenic 14089 rs121913625 14:23898214-23898214 14:23429005-23429005
22 MYH7 NM_000257.4(MYH7):c.1750G>C (p.Gly584Arg)SNV Pathogenic 14090 rs121913626 14:23896932-23896932 14:23427723-23427723
23 MYH7 NM_000257.4(MYH7):c.2221G>C (p.Gly741Arg)SNV Pathogenic 14098 rs121913632 14:23894969-23894969 14:23425760-23425760
24 MYH7 NM_000257.4(MYH7):c.1207C>T (p.Arg403Trp)SNV Pathogenic 14102 rs3218714 14:23898488-23898488 14:23429279-23429279
25 GLA NM_000169.3(GLA):c.640-801G>ASNV Pathogenic 10768 rs199473684 X:100654735-100654735 X:101399747-101399747
26 TNNT2 NM_001276345.2(TNNT2):c.266T>A (p.Ile89Asn)SNV Pathogenic 12408 rs121964855 1:201334766-201334766 1:201365638-201365638
27 TNNI3 NM_000363.5(TNNI3):c.433C>T (p.Arg145Trp)SNV Pathogenic 12426 rs104894724 19:55665514-55665514 19:55154146-55154146
28 TPM1 NM_001018005.2(TPM1):c.523G>A (p.Asp175Asn)SNV Pathogenic 12456 rs104894503 15:63353098-63353098 15:63060899-63060899
29 TTR NM_000371.4(TTR):c.148G>A (p.Val50Met)SNV Pathogenic 13417 rs28933979 18:29172937-29172937 18:31592974-31592974
30 TTR NM_000371.4(TTR):c.238A>G (p.Thr80Ala)SNV Pathogenic 13421 rs121918070 18:29175120-29175120 18:31595157-31595157
31 TTN NM_001267550.2(TTN):c.49345+1G>ASNV Pathogenic 915698 2:179478778-179478778 2:178614051-178614051
32 MYH7 NM_000257.4(MYH7):c.2155C>T (p.Arg719Trp)SNV Pathogenic 14104 rs121913637 14:23895180-23895180 14:23425971-23425971
33 MYH7 NM_000257.4(MYH7):c.2146G>A (p.Gly716Arg)SNV Pathogenic 14105 rs121913638 14:23895189-23895189 14:23425980-23425980
34 MYBPC3 NM_000256.3(MYBPC3):c.1895del (p.Met632fs)deletion Pathogenic 42581 rs397515934 11:47362691-47362691 11:47341140-47341140
35 MYBPC3 NM_000256.3(MYBPC3):c.2040dup (p.Val681fs)duplication Pathogenic 42593 rs397515944 11:47361228-47361229 11:47339677-47339678
36 MYBPC3 NM_000256.3(MYBPC3):c.2096del (p.Pro699fs)deletion Pathogenic 42596 rs397515947 11:47360927-47360927 11:47339376-47339376
37 MYBPC3 NM_000256.3(MYBPC3):c.3617del (p.Gly1206fs)deletion Pathogenic 407336 rs1060501484 11:47354127-47354127 11:47332576-47332576
38 MYBPC3 NM_000256.3(MYBPC3):c.1458-1G>CSNV Pathogenic 522220 rs397515903 11:47364296-47364296 11:47342745-47342745
39 TTN NM_001267550.2(TTN):c.47961del (p.Gly15988fs)deletion Pathogenic 523430 rs1553707780 2:179481655-179481655 2:178616928-178616928
40 UQCRFS1 NM_006003.3(UQCRFS1):c.215-1G>CSNV Pathogenic 619297 rs1568344751 19:29699066-29699066 19:29208159-29208159
41 UQCRFS1 NM_006003.3(UQCRFS1):c.41T>A (p.Val14Asp)SNV Pathogenic 619501 rs1568346416 19:29703985-29703985 19:29213078-29213078
42 UQCRFS1 NM_006003.3(UQCRFS1):c.610C>T (p.Arg204Ter)SNV Pathogenic 619499 rs1242465339 19:29698670-29698670 19:29207763-29207763
43 TTN NM_001267550.2(TTN):c.86076dup (p.Ser28693fs)duplication Pathogenic 519013 rs1285329277 2:179424782-179424783 2:178560055-178560056
44 PKP2 NM_004572.3(PKP2):c.775G>T (p.Glu259Ter)SNV Pathogenic 464432 rs1425855043 12:33031039-33031039 12:32878105-32878105
45 MYBPC3 NM_000256.3(MYBPC3):c.1890del (p.Phe631fs)deletion Pathogenic 626766 rs1565627110 11:47362696-47362696 11:47341145-47341145
46 MYBPC3 NM_000256.3(MYBPC3):c.711C>G (p.Tyr237Ter)SNV Pathogenic 626783 rs774316050 11:47370036-47370036 11:47348485-47348485
47 TAZ NM_000116.5(TAZ):c.688del (p.Arg230fs)deletion Pathogenic 626857 rs1569552936 X:153648588-153648588 X:154420249-154420249
48 PKP2 NM_001005242.3(PKP2):c.2014-1G>CSNV Pathogenic 6756 rs193922674 12:32955491-32955491 12:32802557-32802557
49 PKP2 NM_001005242.3(PKP2):c.2357+1G>ASNV Pathogenic 6757 rs111517471 12:32949042-32949042 12:32796108-32796108
50 PRKAG2 NM_016203.4(PRKAG2):c.905G>A (p.Arg302Gln)SNV Pathogenic 6846 rs121908987 7:151273498-151273498 7:151576412-151576412

UniProtKB/Swiss-Prot genetic disease variations for Atrial Standstill 1:

73
# Symbol AA change Variation ID SNP ID
1 GJA5 p.Pro88Ser VAR_035013 rs121434558
2 GJA5 p.Ala96Ser VAR_035014 rs121434557
3 SCN5A p.Asp1275Asn VAR_026373 rs137854618

Copy number variations for Atrial Standstill 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 20789 1 154318992 154376502 Deletion LMNA Cardiomyopathy
2 39890 10 121400871 121427319 Deletion BAG3 Cardiomyopathy
3 139275 2 178000000 180600000 Loss TTN Cardiomyopathy
4 140112 2 191900000 197400000 Loss HSP40 Cardiomyopathy
5 262125 X 31047265 33267647 Deletion DMD Cardiomyopathy

Expression for Atrial Standstill 1

Search GEO for disease gene expression data for Atrial Standstill 1.

Pathways for Atrial Standstill 1

Pathways related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 TTN TNNT2 TNNI3 RYR2 PLN MYL2
2
Show member pathways
12.41 TNNT2 TNNI3 RYR2 PLN MYL2 MYH7
3
Show member pathways
12.34 RYR2 PLN MYL2 GJA5 ACTC1
4 12.27 TNNT2 TNNI3 LMNA ACTC1
5
Show member pathways
11.98 RYR2 PKP2 LMNA DSP DSG2 DMD
6
Show member pathways
11.67 TTN TNNT2 TNNI3 RYR2 PRKAG2 PLN
7 11.57 TNNT2 TNNI3 RYR2 MYL2 MYH7 ACTC1
8 11.46 TNNT2 TNNI3 MYL2 ACTC1
9 11.4 RYR2 PLN LMNA GJA5 DSP
10 11.36 TTN TNNT2 TNNI3 MYL2 MYBPC3 DMD

GO Terms for Atrial Standstill 1

Cellular components related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.71 TTN RYR2 MYH7 DMD
2 cornified envelope GO:0001533 9.61 PKP2 DSP DSG2
3 intercalated disc GO:0014704 9.56 PKP2 GJA5 DSP DSG2
4 myosin filament GO:0032982 9.51 MYH7 MYBPC3
5 desmosome GO:0030057 9.5 PKP2 DSP DSG2
6 A band GO:0031672 9.49 MYL2 MYBPC3
7 striated muscle thin filament GO:0005865 9.48 TTN TNNT2
8 troponin complex GO:0005861 9.46 TNNT2 TNNI3
9 myofibril GO:0030016 9.46 TNNI3 MYL2 MYH7 DMD
10 cardiac Troponin complex GO:1990584 9.37 TNNT2 TNNI3
11 cardiac myofibril GO:0097512 9.26 TNNT2 TNNI3 MYL2 MYBPC3
12 sarcomere GO:0030017 9.23 TTN TNNT2 TNNI3 RYR2 MYL2 MYH7

Biological processes related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.97 TNNI3 TAZ PKP2 MYL2 GJA5
2 cornification GO:0070268 9.83 PKP2 DSP DSG2
3 cellular calcium ion homeostasis GO:0006874 9.82 TNNI3 RYR2 PLN
4 muscle contraction GO:0006936 9.8 TTN TNNT2 TNNI3 TAZ MYH7
5 regulation of heart rate GO:0002027 9.76 RYR2 MYH7 DMD
6 skeletal muscle contraction GO:0003009 9.75 TNNT2 TNNI3 MYH7
7 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.73 RYR2 PLN DMD
8 regulation of heart rate by cardiac conduction GO:0086091 9.73 PKP2 GJA5 DSP DSG2
9 regulation of the force of heart contraction GO:0002026 9.72 PLN MYL2 MYH7
10 striated muscle contraction GO:0006941 9.71 TTN TNNI3 MYH7
11 ventricular cardiac muscle cell action potential GO:0086005 9.7 RYR2 PKP2 GJA5
12 heart contraction GO:0060047 9.69 TNNI3 MYL2 ACTC1
13 cardiac myofibril assembly GO:0055003 9.67 TTN MYL2 ACTC1
14 regulation of muscle contraction GO:0006937 9.66 TNNT2 TNNI3
15 muscle fiber development GO:0048747 9.65 MYL2 DMD
16 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.65 PLN DMD
17 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.65 RYR2 PKP2 GJA5
18 response to muscle stretch GO:0035994 9.64 RYR2 DMD
19 cardiac muscle tissue morphogenesis GO:0055008 9.63 TTN ACTC1
20 cardiac muscle hypertrophy GO:0003300 9.63 TTN RYR2
21 negative regulation of ATPase activity GO:0032780 9.63 TNNT2 TNNI3 PLN
22 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.63 TNNT2 TNNI3 PKP2 MYL2 MYH7 MYBPC3
23 skeletal muscle thin filament assembly GO:0030240 9.62 TTN ACTC1
24 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.62 TNNI3 RYR2
25 regulation of striated muscle contraction GO:0006942 9.61 MYL2 MYBPC3
26 positive regulation of the force of heart contraction GO:0098735 9.61 RYR2 MYL2
27 regulation of atrial cardiac muscle cell action potential GO:0098910 9.6 RYR2 GJA5
28 regulation of AV node cell action potential GO:0098904 9.59 RYR2 GJA5
29 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.56 RYR2 PKP2 DSP DSG2
30 muscle filament sliding GO:0030049 9.56 TTN TNNT2 TNNI3 MYL2 MYH7 MYBPC3
31 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.54 PKP2 DSP DSG2
32 desmosome organization GO:0002934 9.5 PKP2 DSP DSG2
33 cardiac muscle contraction GO:0060048 9.32 TTN TNNT2 TNNI3 TAZ RYR2 MYL2

Molecular functions related to Atrial Standstill 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.72 TNNT2 TNNI3 MYH7 MYBPC3 DMD
2 myosin heavy chain binding GO:0032036 9.37 MYL2 MYBPC3
3 myosin binding GO:0017022 9.33 MYBPC3 DMD ACTC1
4 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
5 structural constituent of muscle GO:0008307 9.26 TTN MYL2 MYBPC3 DMD
6 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.8 PKP2 DSP DSG2

Sources for Atrial Standstill 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....